The genetics of malignant melanoma: Lessons from mouse and man

被引:200
作者
Chin, L [1 ]
机构
[1] Harvard Univ, Sch Med, Dept Dermatol, Dana Farber Canc Inst,Dept Med Oncol, Boston, MA 02115 USA
关键词
D O I
10.1038/nrc1145
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Therapeutic resistance and proclivity for metastasis are hallmarks of malignant melanoma. Genetic, epidemiological and genomic investigations are uncovering the spectrum of stereotypical mutations that are associated with melanoma and how these mutations relate to risk factors such as ultraviolet exposure. The ability to validate the pathogenetic relevance of these mutations in the mouse, coupled with advances in rational drug design, has generated optimism for the development of effective prevention programmes, diagnostic measures and targeted therapeutics in the near future.
引用
收藏
页码:559 / 570
页数:12
相关论文
共 169 条
[31]   E1A signaling to p53 involves the p19ARF tumor suppressor [J].
de Stanchina, E ;
McCurrach, ME ;
Zindy, F ;
Shieh, SY ;
Ferbeyre, G ;
Samuelson, AV ;
Prives, C ;
Roussel, MF ;
Sherr, CJ ;
Lowe, SW .
GENES & DEVELOPMENT, 1998, 12 (15) :2434-2442
[32]   Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J].
Demetri, GD ;
von Mehren, M ;
Blanke, CD ;
Van den Abbeele, AD ;
Eisenberg, B ;
Roberts, PJ ;
Heinrich, MC ;
Tuveson, DA ;
Singer, S ;
Janicek, M ;
Fletcher, JA ;
Silverman, SG ;
Silberman, SL ;
Capdeville, R ;
Kiese, B ;
Peng, B ;
Dimitrijevic, S ;
Druker, BJ ;
Corless, C ;
Fletcher, CDM ;
Joensuu, H .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :472-480
[33]   Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma [J].
Demunter, A ;
Stas, M ;
Degreef, H ;
De Wolf-Peeters, C ;
van den Oord, JJ .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2001, 117 (06) :1483-1489
[34]   Transcriptional repression - The cancer-chromatin connection [J].
DePinho, RA .
NATURE, 1998, 391 (6667) :533-+
[35]   Pten is essential for embryonic development and tumour suppression [J].
Di Cristofano, A ;
Pesce, B ;
Cordon-Cardo, C ;
Pandolfi, PP .
NATURE GENETICS, 1998, 19 (04) :348-355
[36]  
DONAWHO CK, 1991, CANCER RES, V51, P4176
[37]   Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].
Druker, BJ ;
Talpaz, M ;
Resta, DJ ;
Peng, B ;
Buchdunger, E ;
Ford, JM ;
Lydon, NB ;
Kantarjian, H ;
Capdeville, R ;
Ohno-Jones, S ;
Sawyers, CL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037
[38]   Development of melanocyte precursors from the vertebrate neural crest [J].
Dupin, E ;
Le Douarin, NM .
ONCOGENE, 2003, 22 (20) :3016-3023
[39]  
DURO D, 1995, ONCOGENE, V11, P21
[40]   Cancer revoked: oncogenes as therapeutic targets [J].
Felsher, DW .
NATURE REVIEWS CANCER, 2003, 3 (05) :375-380